The reiteration of a Buy rating and the maintenance of a $60 price target by a reputable analyst like Joseph Stringer could lead to increased investor confidence in Ionis Pharmaceuticals. This positive endorsement is likely to have a favorable impact on the stock price in the short term as it suggests the analyst sees potential for the stock to rise to the target price.